OOIR: Observatory of International Research

Papers

(The H4-Index of Hepatology International is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
The safety profile of endoscopic variceal ligation in patients with esophageal varices	120
HBV in pregnancy: time to consider tenofovir alafenamide (TAF)	101
Metabolically healthy obese and MAFLD: does weight status alone matter?	90
Platelets in acute liver failure: an innocent bystander or instigator?	86
Tenofovir alafenamide-related hyperlipidemia and cardiovascular risk	68
Diagnosis of significant liver fibrosis in patients with chronic hepatitis B using a deep learning-based data integration network	67
N-terminal propeptide of type 3 collagen-based sequential algorithm can identify high-risk steatohepatitis and fibrosis in MAFLD	65
Midodrine plus propranolol versus propranolol alone in preventing first bleed in patients with cirrhosis and severe ascites: a randomized controlled trial	57
Defining the evaluation standards for the cholangiocytic component in cHCC-CCA: a pathology-based perspective	57
Clathrin light chain A facilitates small extracellular vesicle uptake to promote hepatocellular carcinoma progression	49
Pure laparoscopic versus open left lateral hepatectomy in pediatric living donor liver transplantation: a review and meta-analysis	47
Commentary on “Comparison of relaxed verses standard cut-offs of rotational thromboelastometry for guiding blood product use before invasive procedures in advanced cirrhosis: a randomized controlled t	46
Predictive value of soluble PD-1 for HBsAg loss in HbeAg-negative patients with chronic hepatitis B: results from a prospective study	45
Response to: “Is laparoscopic hepatectomy superior to laparotomic hepatectomy? The debate continues”	44
Methodological reflections on vasoconstrictor use in refractory ascites: bridging trial rigor and real-world relevance	44
The promise of incretin-based pharmacotherapies for metabolic dysfunction-associated fatty liver disease	43
Can living donor liver transplantation provide similar outcomes to deceased-donor liver transplantation for hepatocellular carcinoma? A systematic review and meta-analysis	41
p53 regulates glucose metabolic reprogramming in MASLD-related hepatocellular carcinoma via modulating mitochondrial pyruvate carriers	39
Liver stiffness can predict decompensation and need for beta-blockers in compensated cirrhosis: a step beyond Baveno-VI criteria	38
Antioxidant, selenium and risk of nonalcoholic fatty liver disease, more than causality	38
Exosome GLUT1 derived from hepatocyte identifies the risk of non-alcoholic steatohepatitis and fibrosis	37
Efficacy and safety of durvalumab rechallenge in advanced hepatocellular carcinoma patients refractory to prior anti-PD-1 therapy	35
Machine learning models in the prediction of 1-year mortality in patients with advanced hepatocellular cancer on immunotherapy: a proof-of-concept study	35
Distinct on-treatment HCC risks associated with different decompensation events in HBV patients with cirrhosis	35
The impact of an increased Fibrosis-4 index and the severity of hepatic steatosis on mortality in individuals living with diabetes	34

Antibiotic prophylaxis in upper gastrointestinal bleeding with Child-Pugh A cirrhosis: need for objective infection markers and broader studies	34
Good outcomes of living donor liver transplant in primary sclerosing cholangitis: an experience from North India	34
Impact of CT-relevant skeletal muscle parameters on post-liver transplantation survival in patients with hepatocellular carcinoma	34
Breaking bottlenecks: the future of hepatocellular carcinoma clinical trials and therapeutic targets	32
Development of nomograms to predict outcomes for large hepatocellular carcinoma after liver resection	32
APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis	32
Liver-derived extracellular vesicles from patients with hepatitis B virus-related acute-on-chronic liver failure impair hepatic regeneration by inhibiting on FGFR2 signaling via miR-218-5p	31
Letter to the editor: Treating portal vein thrombosis in cirrhosis: is anticoagulation therapy overestimated?	31
Targeting immuno-metabolism and anti-viral immune responses in chronic hepatitis B	31
Reply to: “developing real‑world prognostic models for patients with advanced hepatocellular carcinoma: CRAFITY, mALF and beyond”	31